What is Leerink Partnrs’ Forecast for TENX Q1 Earnings?

Tenax Therapeutics, Inc. (NASDAQ:TENX) – Analysts at Leerink Partnrs issued their Q1 2025 EPS estimates for shares of Tenax Therapeutics in a report released on Wednesday, March 26th. Leerink Partnrs analyst D. Risinger expects that the specialty pharmaceutical company will earn ($1.06) per share for the quarter. The consensus estimate for Tenax Therapeutics’ current full-year earnings is ($0.88) per share. Leerink Partnrs also issued estimates for Tenax Therapeutics’ Q2 2025 earnings at ($1.12) EPS, Q3 2025 earnings at ($3.52) EPS, Q4 2025 earnings at ($4.73) EPS, FY2025 earnings at ($10.46) EPS, FY2026 earnings at ($5.76) EPS, FY2027 earnings at ($4.86) EPS, FY2028 earnings at ($3.08) EPS and FY2029 earnings at ($1.03) EPS.

TENX has been the topic of a number of other research reports. StockNews.com started coverage on shares of Tenax Therapeutics in a research report on Saturday. They set a “sell” rating on the stock. Leerink Partners set a $20.00 price target on shares of Tenax Therapeutics in a report on Monday, March 10th. Finally, William Blair reissued an “outperform” rating on shares of Tenax Therapeutics in a research note on Monday, March 10th. One research analyst has rated the stock with a sell rating, three have assigned a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, Tenax Therapeutics presently has a consensus rating of “Moderate Buy” and an average target price of $18.00.

Tenax Therapeutics Stock Performance

NASDAQ TENX opened at $6.49 on Monday. The company has a market cap of $25.73 million, a P/E ratio of -1.22 and a beta of 2.20. The business’s 50 day moving average price is $6.43 and its 200-day moving average price is $5.44. Tenax Therapeutics has a fifty-two week low of $2.77 and a fifty-two week high of $7.89.

Tenax Therapeutics (NASDAQ:TENX) last issued its quarterly earnings data on Tuesday, March 25th. The specialty pharmaceutical company reported ($0.18) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.52) by $0.34.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the stock. Janus Henderson Group PLC purchased a new stake in Tenax Therapeutics in the 4th quarter valued at about $1,026,000. Sphera Funds Management LTD. bought a new stake in shares of Tenax Therapeutics during the third quarter valued at approximately $101,000. Millennium Management LLC purchased a new stake in shares of Tenax Therapeutics in the fourth quarter valued at approximately $166,000. Geode Capital Management LLC grew its stake in Tenax Therapeutics by 32.4% in the fourth quarter. Geode Capital Management LLC now owns 24,354 shares of the specialty pharmaceutical company’s stock worth $151,000 after purchasing an additional 5,964 shares in the last quarter. Finally, Two Sigma Investments LP purchased a new position in Tenax Therapeutics during the 4th quarter worth $84,000. 1.67% of the stock is currently owned by institutional investors.

Tenax Therapeutics Company Profile

Tenax Therapeutics, Inc develops and commercializes pharmaceutical products containing imatinib for the treatment of pulmonary arterial hypertension in the United States. The company develops TNX-101 (IV), TNX-102, and TNX-103 (levosimendan) that have completed phase II clinical trials for the treatment of patients with pulmonary hypertension associated with heart failure with preserved ejection fraction and associated pulmonary hypertension; and TNX-201 (imatinib), a tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia.